BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage biotechnology company developing autologous cell therapies for neurodegenerative diseases.
We are honored to welcome @PeterPitts, former @US_FDA Associate Commissioner, to BrainStorm's Board of Directors. His expertise will help support our mission to advance NurOwn® for people living with ALS. #NurOwn#Biotech#FDA#ALS
Read more: https://t.co/2xnHjmCaeQ
Lou Gehrig's story is part of our history.
People living with ALS are fighting for their future.
Scientific progress is advancing rapidly. People living with ALS deserve every opportunity to benefit from it. @RCJAPH
https://t.co/Uhe0cZqKkA
#LouGehrigDay#StrikeOutALS
As the #ALS community marks #LouGehrigDay, BrainStorm announced the publication of an article in @RCJAPH examining how advances in science, medicine, and technology are challenging regulatory frameworks to evolve alongside innovation.
Read: https://t.co/QUvIyK6dBy
In 2002, I spoke at an ALS event in DC. After my talk, a patient said to me, "I'll be dead in a year. Please help make a cure possible." I promised that I would. And I intend to keep that promise. https://t.co/R0o5UkbYdB
A Citizen Petition was submitted to the FDA requesting a new review of data supporting NurOwn®.
We remain focused on advancing the ENDURANCE Phase 3b trial and exploring pathways that could bring meaningful options to people living with #ALS.
Here: https://t.co/ObN1fVHbEF
📊 New ALS Survival Data
90% of #ALS participants in EAP for NurOwn® survived over 5 years, compared to the typical 10% survival rate. These real-world findings support the scientific rationale for the upcoming Phase 3b trial under FDA SPA. Read here: https://t.co/1GYZg94SHa
When Anne Snyder’s husband Leonard was diagnosed with ALS, the care team didn’t just give a diagnosis—they gave compassion. Words like “We’ll walk with you” meant everything. Kindness changes everything.
#MomentsThatMattered#Endurance#BetterTogether@youralsnetwork
We’re partnering with @MinarisRM to manufacture NurOwn® for the upcoming Phase 3b #Endurance#ALS trial.
This step ensures aligned strategy and execution as we advance our #mission to bring forward a meaningful treatment. Read here: https://t.co/4NlJ0MVfZ2
#NurOwn
When @cimbura_seide Dad had #ALS, her college equestrian community made sure she never felt alone.
They didn’t just offer words—they booked flights, checked in, and showed up. That’s what compassion looks like.
#MomentsThatMattered#ALSawareness#BetterTogether#EnduranceALS
During today’s $BCLI earnings call, our CEO reflected on a powerful moment from the #ALS Drug Development Summit—Wendy, living with ALS, called every patient a warrior.
We stand with the ALS Community. The ENDURANCE trial is our commitment in action.
The Phase 3b ENDURANCE trial of NurOwn® has been cleared by the @US_FDA under a Special Protocol Assessment (SPA).
This milestone reflects continued progress toward developing a potentially meaningful treatment option.
📄 Full release: https://t.co/r8GM1Z9TgP #EnduranceALS
I found community, understanding, and the strength to keep going.”
Lakeia Nard shares how Many Shades of @iamalsorg helped her feel seen & supported as a caregiver.
Thank you, Lakei for reminding us why #community matters. @ChildrenMelanin#MomentsThatMatter#ALS#caregiver
We’re proud to announce the name of our upcoming Phase 3b ALS clinical trial: ENDURANCE – A Testament to Strength and Perseverance in the Fight Against ALS.
📌 It is posted here: https://t.co/mHK3MdQqF8
The trial is not yet enrolling. We will announce when enrollment begins.